Adjuvant therapy for resectable rectal adenocarcinoma.
The mainstay of treatment for rectal cancer over the past 100 years has been surgical resection. However, for the majority of rectal cancers treated conventionally by resection alone, locoregional recurrence is the major mode of failure. Over the past several decades, significant progress has been made in developing effective adjuvant regimens. In the United States, postoperative chemoradiation is standard treatment for T3 or node-positive patients. However, preoperative radiation with or without chemotherapy decreases local recurrence, increases sphincter preservation, and may improve survival. The purpose of this article is to review the role of adjuvant therapy in resectable rectal cancers and to update the status of ongoing randomized trials.
Department of Radiation Oncology, Beth Israel Medical Center, New York, New York, USA.
K S
KS
Hu
L B
LB
Harrison
D000230:Adenocarcinoma / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000628:therapy*